Oragenics Inc.

We are a development-stage company dedicated to the research and development of nasal delivery pharmaceutical medications in neurology. Our lead product, the ONP-002 drug, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and it has been shown in animal models that it can cross the blood-brain barrier rapidly to reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Current securities

1. Regulation FD Disclosure · Other EventsSep 16, 2026
2. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other EventsAug 28, 2026
3. Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersJul 6, 2026
4. DEFA14A filingMay 20, 2026
5. DEF 14A filingMay 20, 2026